138 related articles for article (PubMed ID: 31464957)
21. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma.
Kim HD; An J; Kim JH; Gwon DI; Shin JH; Ko GY; Yoon HK; Sung KB; Kim KM; Lee HC
J Vasc Interv Radiol; 2016 Apr; 27(4):504-13. PubMed ID: 26896049
[TBL] [Abstract][Full Text] [Related]
22. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
23. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
[TBL] [Abstract][Full Text] [Related]
24. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization.
Kim NH; Lee T; Cho YK; Kim BI; Kim HJ
J Gastroenterol Hepatol; 2018 Jul; 33(7):1397-1406. PubMed ID: 29314222
[TBL] [Abstract][Full Text] [Related]
25. Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome.
Kim IS; Lim YS; Lee HC; Suh DJ; Lee YJ; Lee SG
Aliment Pharmacol Ther; 2008 Feb; 27(4):338-45. PubMed ID: 18047564
[TBL] [Abstract][Full Text] [Related]
26. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
Kaplan DE; Mehta R; D'Addeo K; Gade TP; Taddei TH
J Vasc Interv Radiol; 2018 Apr; 29(4):540-549.e4. PubMed ID: 29477619
[TBL] [Abstract][Full Text] [Related]
27. Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: A meta-analysis.
Si T; Chen Y; Ma D; Gong X; Guan R; Shen B; Peng C
J Gastroenterol Hepatol; 2017 Jul; 32(7):1286-1294. PubMed ID: 28085213
[TBL] [Abstract][Full Text] [Related]
28. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M
Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199
[TBL] [Abstract][Full Text] [Related]
29. Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study.
Hyun HK; Cho EJ; Park SY; Hong YM; Kim SS; Kim HY; Heo NY; Park JG; Sinn DH; Kang W; Jeong SW; Song MJ; Park H; Lee D; Lee YS; Cho SB; An CS; Rhee HJ; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee JH; Yu SJ; Kim YJ; Yoon JH; Tak WY; Kweon YO; Yoon KT; Cho M; Cheong JY; Park SH; Kim SU;
Dig Dis Sci; 2021 Jul; 66(7):2427-2438. PubMed ID: 32856240
[TBL] [Abstract][Full Text] [Related]
30. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
[TBL] [Abstract][Full Text] [Related]
31. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
[TBL] [Abstract][Full Text] [Related]
33. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.
Zhou C; Wang R; Ding Y; Du L; Hou C; Lu D; Hao L; Lv W
Int J Clin Exp Pathol; 2014; 7(5):2579-86. PubMed ID: 24966972
[TBL] [Abstract][Full Text] [Related]
35. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
36. Acute kidney injury after platinum-based transcatheter arterial chemoembolization and transarterial infusion chemotherapy in patients with hepatocellular carcinoma.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Jpn J Clin Oncol; 2020 Jan; 50(1):36-43. PubMed ID: 31665483
[TBL] [Abstract][Full Text] [Related]
37. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
40. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]